Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19364654 | METHODS OF TREATING DISORDERS USING CSF1R INHIBITORS | October 2025 | February 2026 | Allow | 4 | 1 | 0 | No | No |
| 19323694 | STIMULANT COMPOSITION AND PROCESS FOR MAKING SAME | September 2025 | December 2025 | Allow | 4 | 0 | 0 | Yes | No |
| 19308863 | RAS INHIBITORS | August 2025 | December 2025 | Allow | 4 | 1 | 0 | No | No |
| 19280031 | IMMUNO-THERAPEUTIC CHEMICAL COMPOSITIONS AND USES THEREOF | July 2025 | December 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19278636 | DOSAGE REGIMENS FOR BENZGALANTAMINE | July 2025 | October 2025 | Allow | 3 | 0 | 0 | No | No |
| 19274280 | METHODS OF TREATING ISCHEMIC STROKE AT RISK FOR CEREBRAL OR CEREBELLAR EDEMA | July 2025 | February 2026 | Allow | 7 | 1 | 0 | No | No |
| 19264673 | TREATMENT OF PROSTATE CANCER | July 2025 | September 2025 | Allow | 2 | 0 | 0 | No | No |
| 19263324 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | July 2025 | January 2026 | Allow | 6 | 1 | 0 | No | No |
| 19249959 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | June 2025 | October 2025 | Allow | 4 | 1 | 0 | No | No |
| 19246287 | AMORPHOUS CABOZANTINIB PARTICLES AND USES THEREOF | June 2025 | January 2026 | Allow | 7 | 2 | 0 | No | No |
| 19244143 | COMBINATION THERAPY FOR A DOPAMINE AGONIST | June 2025 | December 2025 | Allow | 5 | 2 | 0 | Yes | No |
| 19237400 | MIRDAMETINIB TREATMENT | June 2025 | March 2026 | Abandon | 9 | 1 | 0 | No | No |
| 19231124 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | June 2025 | September 2025 | Allow | 4 | 0 | 0 | No | No |
| 19229702 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | June 2025 | January 2026 | Allow | 8 | 1 | 0 | No | No |
| 19228293 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | June 2025 | August 2025 | Allow | 3 | 0 | 0 | No | No |
| 19228565 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | June 2025 | August 2025 | Allow | 3 | 0 | 0 | No | No |
| 19228179 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | June 2025 | August 2025 | Allow | 3 | 0 | 0 | No | No |
| 19100372 | CRYSTAL FORM OF SPIROCYCLIC AMINE ARYL PHOSPHORUS OXIDE COMPOUND AND PREPARATION METHOD THEREFOR | June 2025 | March 2026 | Allow | 13 | 2 | 0 | No | No |
| 19225991 | COMPOSITIONS AND METHODS FOR USING ENGINEERED DEUBIQUITINASES FOR PROBING UBIQUITIN-DEPENDENT CELLULAR PROCESSES | June 2025 | November 2025 | Allow | 5 | 1 | 0 | No | No |
| 19224111 | AQUEOUS BIOCIDAL COMPOSITION | May 2025 | October 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19206788 | METHODS OF TREATING ISCHEMIC STROKE AT RISK FOR CEREBRAL OR CEREBELLAR EDEMA | May 2025 | July 2025 | Allow | 2 | 1 | 0 | No | No |
| 19192108 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | April 2025 | January 2026 | Allow | 9 | 1 | 0 | No | No |
| 19187858 | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | April 2025 | May 2025 | Allow | 1 | 0 | 0 | No | No |
| 19182966 | MORPHIC FORMS OF TRILACICLIB AND METHODS OF MANUFACTURE THEREOF | April 2025 | October 2025 | Allow | 6 | 1 | 0 | No | No |
| 19182985 | MORPHIC FORMS OF TRILACICLIB AND METHODS OF MANUFACTURE THEREOF | April 2025 | October 2025 | Allow | 6 | 1 | 0 | No | No |
| 19182977 | MORPHIC FORMS OF TRILACICLIB AND METHODS OF MANUFACTURE THEREOF | April 2025 | October 2025 | Allow | 6 | 1 | 0 | No | No |
| 19182463 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | April 2025 | August 2025 | Allow | 4 | 1 | 0 | No | No |
| 19172172 | PHARMACEUTICAL FORMULATIONS OF A BRUTON'S TYROSINE KINASE INHIBITOR | April 2025 | September 2025 | Allow | 6 | 2 | 0 | Yes | No |
| 19171162 | METHODS OF USING RADIPRODIL IN THE TREATMENT OF DISORDERS | April 2025 | July 2025 | Allow | 3 | 0 | 0 | No | No |
| 19098294 | Selective Serotonin Receptor Modulators and Methods of Making and Using the Same | April 2025 | January 2026 | Allow | 9 | 2 | 1 | Yes | No |
| 19096247 | (S)-2-((S)-(2-ETHOXYPHENOXY)(PHENYL)METHYL)-4-NITROSOMORPHOLINE | March 2025 | January 2026 | Allow | 9 | 1 | 1 | No | No |
| 19094703 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | March 2025 | June 2025 | Allow | 3 | 2 | 0 | No | No |
| 19094716 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | March 2025 | June 2025 | Allow | 3 | 1 | 0 | No | No |
| 19094756 | METHODS FOR MAKING AND USING ENDOXIFEN | March 2025 | September 2025 | Allow | 5 | 1 | 0 | No | No |
| 19094187 | HETEROCYCLIC GLP-1R AGONISTS | March 2025 | December 2025 | Allow | 8 | 1 | 1 | No | No |
| 19087148 | METHODS OF TREATMENT | March 2025 | August 2025 | Allow | 5 | 1 | 0 | No | No |
| 19081876 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | March 2025 | December 2025 | Allow | 9 | 1 | 0 | No | No |
| 19079727 | METHODS OF TREATING DISORDERS USING CSF1R INHIBITORS | March 2025 | July 2025 | Allow | 4 | 1 | 0 | No | No |
| 19076811 | METHODS AND SYSTEMS FOR TREATING DISEASE USING AN ATR/CHK1 SIGNALING PATHWAY INHIBITOR | March 2025 | July 2025 | Allow | 4 | 0 | 0 | No | No |
| 19074260 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | March 2025 | July 2025 | Allow | 4 | 1 | 0 | No | No |
| 19067616 | METHODS OF TREATING FIBROTIC LIVER DISEASES OR CONDITIONS WITH INDEGLITAZAR | February 2025 | July 2025 | Allow | 5 | 0 | 0 | No | No |
| 19060522 | Piperidine Urea Derivatives for Use as Inotropic Agents | February 2025 | November 2025 | Allow | 9 | 2 | 0 | No | No |
| 19055916 | METHODS OF TREATING MIGRAINE | February 2025 | November 2025 | Allow | 9 | 1 | 1 | No | No |
| 19050547 | TREATMENT FOR HEART FAILURE WITH PRESERVED EJECTION FRACTION WITH GUANETHIDINE AND GUANADREL | February 2025 | June 2025 | Allow | 4 | 1 | 0 | No | No |
| 19045070 | METHODS FOR TREATING A FATTY LIVER DISEASE | February 2025 | May 2025 | Allow | 4 | 1 | 0 | No | No |
| 19039220 | METHODS OF TREATING ISCHEMIC STROKE AT RISK FOR CEREBRAL OR CEREBELLAR EDEMA | January 2025 | May 2025 | Allow | 3 | 1 | 0 | No | No |
| 19031763 | CONJUGATE OF POLYPEPTIDE AND SMALL MOLECULE TARGETING KRAS AND ANTI-CANCER APPLICATION THEREOF | January 2025 | February 2026 | Abandon | 13 | 1 | 0 | No | No |
| 19030296 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | January 2025 | January 2026 | Allow | 12 | 2 | 0 | Yes | No |
| 19024972 | INHIBITORS OF MPTP | January 2025 | July 2025 | Allow | 6 | 1 | 1 | No | No |
| 19020628 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | January 2025 | June 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19018817 | COMPOUNDS AS GLP-1R AGONISTS | January 2025 | June 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19018805 | COMPOUNDS AS GLP-1R AGONISTS | January 2025 | June 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19018773 | COMPOUNDS AS GLP-1R AGONISTS | January 2025 | May 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19018754 | COMPOUNDS AS GLP-1R AGONISTS | January 2025 | May 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19018788 | COMPOUNDS AS GLP-1R AGONISTS | January 2025 | June 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19013174 | NOVEL USE OF MELANOCORTIN-1 RECEPTOR AGONIST | January 2025 | September 2025 | Allow | 9 | 1 | 0 | No | No |
| 19005181 | METHODS OF TREATING ACUTE DEPRESSION AND ANXIETY | December 2024 | August 2025 | Allow | 7 | 2 | 0 | No | No |
| 18999662 | EPINEPHRINE COMPOSITIONS AND CONTAINERS | December 2024 | May 2025 | Allow | 4 | 1 | 0 | No | No |
| 18990351 | METHODS OF IMPROVING RENAL FUNCTION | December 2024 | June 2025 | Allow | 6 | 1 | 0 | No | No |
| 18986934 | METHOD OF TREATING CANCER WITH A SELENIDE | December 2024 | March 2025 | Allow | 3 | 1 | 0 | No | No |
| 18973646 | MORPHIC FORMS OF TRILACICLIB AND METHODS OF MANUFACTURE THEREOF | December 2024 | October 2025 | Abandon | 10 | 1 | 0 | No | No |
| 18968681 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | December 2024 | November 2025 | Abandon | 11 | 2 | 0 | Yes | No |
| 18958449 | Compositions And Methods For The Treatment Of Depression | November 2024 | June 2025 | Allow | 7 | 1 | 0 | No | No |
| 18950383 | Oral Brexanolone Compositions and Methods of Preparation and Use | November 2024 | February 2026 | Allow | 14 | 3 | 0 | No | Yes |
| 18949037 | Methods for Providing Rapid Relief of Motor Fluctuations in a Parkinson's Disease Patient | November 2024 | July 2025 | Allow | 8 | 1 | 0 | No | No |
| 18949105 | PARTICULATE COMPOSITION | November 2024 | January 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 18948977 | Compositions and Methods for Treatment and Prevention of Actinic Keratosis Using Copper Chlorin | November 2024 | July 2025 | Allow | 8 | 1 | 1 | No | No |
| 18945317 | GLABRIDIN COMPOSITION WITH HIGH SKIN PERMEABILITY, AND PREPARATION METHOD AND USE THEREOF | November 2024 | February 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 18943210 | NASAL COMPOSITIONS COMPRISING ALCAFTADINE | November 2024 | March 2025 | Allow | 4 | 0 | 0 | No | No |
| 18941137 | PHARMACEUTICAL COMPOSITIONS COMPRISING NILOTINIB | November 2024 | June 2025 | Allow | 7 | 2 | 0 | Yes | No |
| 18938942 | Oral Testosterone Therapy | November 2024 | January 2025 | Allow | 2 | 1 | 0 | No | No |
| 18937891 | TREATMENT OF PROSTATE CANCER | November 2024 | May 2025 | Allow | 6 | 1 | 0 | No | No |
| 18935332 | SOLID FORMS OF MACROCYCLIC COMPOUNDS, SALTS AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE SAME | November 2024 | July 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 18913072 | METHODS OF TREATING MIGRAINE | October 2024 | June 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 18913492 | METHODS OF TREATING MIGRAINE | October 2024 | November 2025 | Allow | 13 | 3 | 1 | No | No |
| 18899500 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | September 2024 | December 2024 | Allow | 3 | 1 | 0 | No | No |
| 18895208 | METHOD OF TREATING CANCER IN A SUBJECT | September 2024 | November 2024 | Allow | 2 | 0 | 0 | No | No |
| 18892208 | KRAS MODULATORS AND USES THEREOF | September 2024 | March 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18818317 | STABLE PSILOCIN SALTS, ESTERS AND CONJUGATES AND USES THEREOF | August 2024 | November 2024 | Allow | 2 | 1 | 0 | No | No |
| 18817153 | Methods of Treatment With an Iboga Alkaloid | August 2024 | July 2025 | Allow | 10 | 2 | 1 | No | No |
| 18811355 | USE OF GLUTAMATE 2B RECEPTOR ANTAGONISTS AND SIGMA RECEPTOR AGONISTS AS ANTITUSSIVES | August 2024 | September 2025 | Allow | 13 | 2 | 1 | No | No |
| 18811171 | Compositions and Methods for Treating Hypertension by Modulating Endocrine Activity | August 2024 | November 2024 | Allow | 3 | 1 | 0 | No | No |
| 18811674 | COMPOSITIONS AND METHODS FOR USING ENGINEERED DEUBIQUITINASES FOR PROBING UBIQUITIN-DEPENDENT CELLULAR PROCESSES | August 2024 | March 2025 | Allow | 6 | 1 | 0 | No | No |
| 18811682 | COMPOSITIONS AND METHODS FOR USING ENGINEERED DEUBIQUITINASES FOR PROBING UBIQUITIN-DEPENDENT CELLULAR PROCESSES | August 2024 | March 2025 | Allow | 7 | 1 | 0 | No | No |
| 18838986 | MORPHOLINE-LIKE MONOAMINE RELEASERS | August 2024 | May 2025 | Allow | 9 | 1 | 0 | No | No |
| 18727731 | USE OF ANTI-IDIOPATHIC PULMONARY FIBROSIS DRUG NINTEDANIB IN TREATMENT OF TUBERCULOSIS | August 2024 | February 2026 | Abandon | 20 | 2 | 0 | No | No |
| 18796081 | COMPOSITIONS AND METHODS FOR USING ENGINEERED DEUBIQUITINASES FOR PROBING UBIQUITIN-DEPENDENT CELLULAR PROCESSES | August 2024 | January 2025 | Allow | 6 | 1 | 0 | No | No |
| 18790458 | Compounds Useful as RET Inhibitors | July 2024 | August 2025 | Abandon | 12 | 0 | 0 | No | No |
| 18778617 | AGENTS THAT TARGET TELOMERASE REVERSE TRANSCRIPTASE (TERT) FOR TREATING CANCER AND SENSITIZING CANCER CELLS TO GENOTOXIC THERAPY | July 2024 | June 2025 | Allow | 11 | 2 | 1 | Yes | No |
| 18775916 | CRYSTALLINE FORMS OF (S, E)-4-(DIMETHYLAMINO)-N-(3-(4-(2-HYDROXY-1-PHENYLETHYLAMINO)-6-PHENYLFURO[2,3-D]PYRIMIDIN-5-YL)PHENYL)BUT-2-ENAMIDE FREE BASE | July 2024 | October 2024 | Abandon | 3 | 1 | 0 | No | No |
| 18771595 | METHODS OF TREATING FIBROTIC LIVER DISEASES OR CONDITIONS WITH INDEGLITAZAR | July 2024 | November 2024 | Allow | 4 | 0 | 0 | No | No |
| 18765632 | DOSAGE FORMS OF MIRDAMETINIB | July 2024 | July 2025 | Allow | 12 | 1 | 0 | No | No |
| 18763671 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF A CANCER | July 2024 | December 2024 | Allow | 5 | 1 | 0 | No | No |
| 18761732 | METHOD FOR PRODUCING GLYCERIDES OF HYDROXYCARBOXYLIC ACIDS | July 2024 | July 2025 | Allow | 13 | 1 | 0 | Yes | No |
| 18762588 | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | July 2024 | October 2025 | Abandon | 16 | 1 | 0 | No | No |
| 18761559 | DEUTERATED ORGANIC COMPOUNDS AND USES THEREOF | July 2024 | March 2025 | Allow | 8 | 1 | 0 | Yes | No |
| 18758242 | METHODS FOR TREATING HETEROTOPIC OSSIFICATION | June 2024 | September 2024 | Allow | 3 | 0 | 0 | No | No |
| 18758904 | TREATMENT OF PROSTATE CANCER | June 2024 | August 2024 | Allow | 2 | 0 | 0 | No | No |
| 18758358 | GAMMA-HYDROXYBUTYRATE COMPOSITIONS HAVING IMPROVED PHARMACOKINETICS IN THE FED STATE | June 2024 | October 2024 | Allow | 4 | 1 | 0 | Yes | No |
| 18758344 | GAMMA-HYDROXYBUTYRATE COMPOSITIONS HAVING IMPROVED PHARMACOKINETICS IN THE FED STATE | June 2024 | October 2024 | Allow | 4 | 1 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1629.
With a 21.3% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 17.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Art Unit 1629 is part of Group 1620 in Technology Center 1600. This art unit has examined 12,342 patent applications in our dataset, with an overall allowance rate of 57.2%. Applications typically reach final disposition in approximately 28 months.
Art Unit 1629's allowance rate of 57.2% places it in the 13% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.
Applications in Art Unit 1629 receive an average of 1.86 office actions before reaching final disposition (in the 46% percentile). The median prosecution time is 28 months (in the 63% percentile).
When prosecuting applications in this art unit, consider the following:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.